Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: A preliminary analysis of the prothrombin fragment 1+2 levels

Hori, 2012, Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study, Circ J, 76, 2104, 10.1253/circj.CJ-12-0454 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Yeh, 2012, Oral direct factor Xa inhibitors, Circ Res, 111, 1069, 10.1161/CIRCRESAHA.112.276741 Garcia, 2010, The new oral anticoagulants, Blood, 115, 15, 10.1182/blood-2009-09-241851 Francart, 2014, Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels, Thromb Haemost, 111, 1133, 10.1160/TH13-10-0871 Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 2010, Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version, Circ J, 74, 2479, 10.1253/circj.CJ-88-0001 Rosendaal, 1993, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, 69, 236, 10.1055/s-0038-1651587 Naruse, 2013, Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range, Circ Cardiovasc Interv, 6, 444, 10.1161/CIRCINTERVENTIONS.113.000179 Suzuki, 2014, Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time, Circ J, 78, 763, 10.1253/circj.CJ-13-1380 Aronson, 1977, Generation of the combined prothrombin activation peptide (F1–2) during the clotting of blood and plasma, J Clin Invest, 60, 1410, 10.1172/JCI108902 Pelzer, 1991, Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide, Thromb Haemost, 65, 153, 10.1055/s-0038-1647475 Yasaka, 2012, J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan, Circ J, 76, 2086, 10.1253/circj.CJ-12-0923 Inoue, 2013, Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry, Circ J, 77, 2264, 10.1253/circj.CJ-13-0290 Karkouti, 2010, The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study, Anesth Analg, 110, 1533, 10.1213/ANE.0b013e3181db7991 Tagawa, 2008, Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy, BJU Int, 102, 1086, 10.1111/j.1464-410X.2008.07780.x Lip, 1995, Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment, Br Heart J, 73, 527, 10.1136/hrt.73.6.527 Sadanaga, 2010, Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy, J Am Coll Cardiol, 55, 2225, 10.1016/j.jacc.2009.12.049 Nozawa, 2006, D-dimer level influences thromboembolic events in patients with atrial fibrillation, Int J Cardiol, 109, 59, 10.1016/j.ijcard.2005.05.049 Vene, 2003, High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy, Thromb Haemost, 90, 1163, 10.1160/TH03-06-0363 Nakatani, 2012, Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients, Circ J, 76, 317, 10.1253/circj.CJ-11-0885 Mahé, 2002, D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation, Thromb Res, 107, 1, 10.1016/S0049-3848(02)00184-6